Braf, Pfizer and colorectal cancer

Pfizer builds on Braftovi bowel cancer OK with survival data
Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer last month, and it already has survival data that could see that converted to a full license.
Pfizer announces positive phase 3 results for Braftovi regimen in colorectal cancer
Pfizer has announced that its Braftovi (encorafenib) regimen significantly improved both progression-free and overall survival in a late-stage colorectal cancer (CRC) study.
Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil,
Pfizer’s Braftovi extends survival in colorectal cancer
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello! Today, we take a look
Pfizer's BRAFTOVI Regimen Boosts Survival in Phase 3 Trial
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of
Pfizer: BRAFTOVI Combination Regimen Shows Significant Improvement In PFS In Phase 3 Trial In MCRC
Drug major Pfizer Inc. (PFE) announced Monday positive topline results from the progression-free survival or PFS analysis of the
Pfizer Trial For Colorectal Cancer Treatment Shows Improved Survival In Late-Stage Study
Pfizer's Braftovi combination showed significant survival benefits in a Phase 3 study for BRAF V600E-mutant metastatic colorectal cancer.
Pfizer reports positive Phase 3 results for Braftovi
Pfizer (NYSE:PFE) reported positive topline results from a Phase 3 study of its drug Braftovi, also known as encorafenib, in the treatment of a certain type of colorectal cancer. The study, called BREAKWATER,
Pfizer’s Braftovi improves survival in Phase 3 colorectal cancer trial
Pfizer (PFE) announced positive topline results from the progression-free survival – PFS – analysis of the Phase 3 BREAKWATER study of Braftovi
Pfizer's BRAFTOVI shows promise in colorectal cancer trial
NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with a market capitalization of $150 billion and annual revenue exceeding $59 billion, announced today that its Phase 3 BREAKWATER study of BRAFTOVI (encorafenib) in combination with cetuximab and mFOLFOX6 has yielded positive results for patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation.
Hosted on MSN2h
PFE's Colorectal Cancer Drug Meets Other Dual Primary Goal of PFS
Pfizer PFE announced positive top-line results from the progression-free survival (PFS) analysis of a late-stage study of its ...
BioPharma Dive1d
Pfizer drug acquired in $11B buyout confirms benefit in colon cancer
The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...
FiercePharma1d
Pfizer's Braftovi combo on track for full approval in win for FDA's Project FrontRunner
Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in ...
GlobalData on MSN1d
Pfizer’s colon cancer combo approval further supported by Phase III win
Pfizer’s metastatic colorectal cancer (mCRC) combination therapy has met one of the primary endpoints of improving ...
Pfizer's Groundbreaking Cancer Drug Hits a Major Milestone--What It Means for Investors
BRAFTOVI's FDA Approval Sparks Hope for BRAF V600E-mutant Colorectal Cancer Patients and Sets Pfizer Up for Explosive Growth ...